Metropolitan Life Insurance CO Monte Rosa Therapeutics, Inc. Transaction History

Metropolitan Life Insurance CO

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$5.95 - $8.21 $1,826 - $2,520	-307 Reduced 14.43%	1,820 $14,000
Q4 2022 Jun 14, 2023	BUY	$6.71 - $9.72 $2,059 - $2,984	307 Added 16.87%	2,127 $16.2 Million
Q3 2022 Jun 14, 2023	BUY	$7.17 - $12.16 $2,201 - $3,733	307 Added 16.87%	2,127 $17.4 Million
Q2 2022 Jun 20, 2023	BUY	$6.15 - $14.99 $1,888 - $4,601	307 Added 16.87%	2,127 $20,000
Q1 2022 Jun 20, 2023	BUY	$10.36 - $20.41 $3,180 - $6,265	307 Added 16.87%	2,127 $29,000
Q1 2022 Mar 30, 2023	SELL	$10.36 - $20.41 $15,239 - $30,023	-1,471 Reduced 40.88%	2,127 $29,000
Q1 2022 May 12, 2022	BUY	$10.36 - $20.41 $22,035 - $43,412	2,127 New	2,127 $30,000
Q4 2021 Feb 15, 2022	SELL	$16.28 - $27.15 $58,575 - $97,685	-3,598 Closed	0 $0
Q3 2021 Jun 21, 2023	BUY	$18.59 - $42.21 $33,053 - $75,049	1,778 Added 97.69%	3,598 $80,000
Q3 2021 Mar 30, 2023	BUY	$18.59 - $42.21 $27,345 - $62,090	1,471 Added 69.16%	3,598 $80,000
Q3 2021 Nov 15, 2021	BUY	$18.59 - $42.21 $66,886 - $151,871	3,598 New	3,598 $80,000

43.9M

141K

31.2K

Ticker GLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,713,900
Market Cap $329M
Description
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.